Skip to content
The Policy VaultThe Policy Vault

KineretMedical Mutual

Still’s Disease

Initial criteria

  • Patient meets ONE of the following: (1) Has tried one corticosteroid AND had an inadequate response to one conventional synthetic DMARD (e.g., methotrexate) given for ≥2 months or was intolerant; OR (2) Has moderate to severe active systemic features; OR (3) Has active systemic features with concerns of progression to MAS
  • Kineret is prescribed by or in consultation with a rheumatologist
  • Site of care medical necessity is met

Reauthorization criteria

  • Patient has responded (e.g., improved limitation of motion; less joint pain or tenderness; decreased duration of morning stiffness or fatigue; improved function or activities of daily living; reduced dosage of corticosteroids), as determined by the prescriber
  • Site of care medical necessity is met

Approval duration

initial 6 months; reauth 1 year